Aolu Pharma completed a $100 million Series A financing.

36Kr learned that "Arro Pharmaceuticals" announced today that it successfully completed a $100 million Series A financing in June 2025. This round of financing was jointly funded by Temasek's wholly-owned subsidiary, Temasek Life Sciences, Lilly Asia Ventures, Pfizer Ventures, and Sirona Capital. The funds raised in this round will be used to accelerate Arro Pharmaceuticals' differentiated pipeline layout, focusing on addressing major unmet clinical needs in areas such as immunology and inflammation, and oncology. Meanwhile, the funds will also be used to enhance the capabilities of the company's R & D center.